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Background
Highly active antiretroviral therapy (HAART) alone or in
combination with systemic chemotherapy has been
shown to be effective therapy for AIDS-associated Kaposi
sarcoma (KS) in resource-rich countries. It is not known
whether HAART or chemotherapy regimens available in
resource-poor regions are effective in areas where KS is
hyperendemic and typically more aggressive. Therefore,
we conducted a retrospective cohort study to evaluate
clinical response among patients with AIDS-associated KS
treated with HAART alone or in combination with chem-
otherapy in Uganda.
Methods
Records of patients with AIDS-associated KS who had
attended the Infectious Disease Institute (IDI) in Kam-
pala, Uganda, for HIV care between January 2004 and
December 2006 were linked to records at the Uganda
Cancer Institute (UCI). Patients ≥18 years were eligible if
they had histologically or clinically confirmed KS, HIV
infection, and ≥1 KS visit after the initial diagnosis prior
to December 2006. Demographic and clinical informa-
tion were abstracted from records at both institutions.
CD4 T-cell count during follow-up and HAART informa-
tion was obtained from the IDI, while chemotherapy
details were obtained from the UCI. Cox's proportional
hazards models were used to identify predictors of
improvement and resolution of KS disease separately.
Results
We identified 177 patients with a diagnosis of KS and ≥1
KS visit after diagnosis at either the IDI or UCI. Approxi-
mately half (53%) were female and the median age was
35 years. At the time of KS diagnosis, 94 (50%) had a BMI
<18.5 kg/m2, 150 (85%) had a Karnofsky score ≥70, 95
(54%) had T1 tumor stage, 45 (25%) had macular lesions,
50 (28%) had nodular lesions, and 10 (6%) had fungat-
ing lesions. Ninety-six (54%) had KS lesions in >1 loca-
tion and 66 (37%) had ≥10 lesions. The median CD4 T-
cell count was 87 cells/mm3 (Interquartile range (IQR):
17–230). One year following KS diagnosis, the cumula-
tive probability of improvement was 0.71 (95% CI: 0.63–
0.79) and resolution was 0.08 (95% CI: 0.03–0.13). After
two years, the cumulative probability of resolution was
0.28 (95% CI: 0.17–0.39). In univariate analyses, none of
the baseline characteristics (sex, age, employment status,
body mass index (BMI), Karnofsky score, and CD4 T-cell
count) were associated with either improvement or reso-
lution. Three clinical factors were associated with
improvement: having lesions on the upper extremities
(HR = 1.7, 95% CI: 1.1–2.6, p = 0.001), lesions on the
hard palate (HR = 1.5, 95% CI: 1.0–2.3, p = 0.05), and
lesions in >1 location (HR = 1.6, 95% CI: 1.0–2.5, p =
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0.05). Three different clinical factors were associated with
a decreased risk of resolution in univariate analyses: hav-
ing nodular lesions (HR = 0.19, 95% CI: 0.04–0.87, p =
0.03), lesions on the lower extremities (HR = 0.38, 95%
CI: 0.15–0.96, p = 0.04), and ≥10 lesions (HR = 0.30, 95%
CI: 0.09–0.94, p = 0.04). Both HAART and chemotherapy
were associated with improvement of disease, but only
HAART was associated with resolution in univariate anal-
yses. In multivariate analyses, male sex was the only vari-
able other than HAART and chemotherapy that was
independently associated with increased risk of improve-
ment (HR = 2.0, 95% CI: 1.3–3.1, p = 0.002). For resolu-
tion, having a low BMI (<18.5, HR = 0.15, 95% CI: 0.06–
0.39, p < 0.0001) and lesions located on the lower extrem-
ities (HR = 0.12, 95% CI: 0.03–0.43, p = 0.001) were inde-
pendently associated with a decreased risk of disease
resolution. Among patients on HAART, those receiving
efavirenz- and protease inhibitor-containing HAART regi-
mens were 6.9 (95% CI: 1.8–27, p = 0.006) and 14 times
(95% CI: 1.2–172, p = 0.04) more likely to experience dis-
ease resolution compared to those receiving Triomune
(stavudine, lamivudine, nevirapine). There was a trend
towards a better chance of KS resolution with increasing
dosage of chemotherapy (HR = 1.02, 95% CI: 1.00–1.05,
p = 0.1).
Conclusion
HAART, used alone or in combination with systemic
chemotherapy, is effective therapy for epidemic KS in
Uganda. While the majority of patients experience
improvements in KS lesions during the first two years of
therapy, a very small minority resolved their disease. Fac-
tors such as the burden and location of lesions, gender,
and under-nutrition may impact the success of KS ther-
apy. Our data also suggest that the individual components
of HAART regimens may have differential effects on KS
response, with the most widely available drug in resource-
limited settings (Triomune) showing less effectiveness
than other antiretroviral combinations. Additional stud-
ies are required to define the optimal treatment of KS in
endemic areas.Page 2 of 2
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